Skip to main content
Erschienen in: Annals of Hematology 6/2017

09.03.2017 | Original Article

Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease

verfasst von: Xin-xin Cao, Qi Meng, Hao Cai, Tian-Hua He, Cong-li Zhang, Wei Su, Jian Sun, Yue Li, Wei Xu, Dao-bin Zhou, Jian Li

Erschienen in: Annals of Hematology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

A broad spectrum of diseases are associated with IgM monoclonal gammopathy, including Waldenstrom macroglobulinemia (WM), various types of B cell non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM), primary amyloidosis (AL), and monoclonal gammopathy of undetermined significance (MGUS); these are called IgM monoclonal gammopathy related diseases (IgM-RD). We investigated MYD88 L265P and WHIM-like CXCR4 mutations in various IgM-RD. Patients with serum immunofixation electrophoresis confirmed IgM monoclonal gammopathy who had enough material for DNA extraction and presented between January 2008 and October 2016 at Peking Union Medical College Hospital were enrolled in this cohort. We performed real-time allele-specific-polymerase chain reaction and Sanger sequencing to explore the presence of MYD88 L265P and WHIM-like CXCR4 mutations. One hundred and twelve patients (64 male and 48 female patients) were included in this retrospective study. The median age at diagnosis was 62 years (range, 30–84 years). In total, 64 patients (57.1%) carried the MYD88 L265P mutation and 14 patients (12.5%) carried the CXCR4 WHIM-like mutation. We identified the MYD88 L265P somatic variant in cases with WM (39/42), MGUS (8/18), NHL (14/41, including 4/13 diffuse large B cell lymphoma (DLBCL), 1/8 mucosa-associated lymphoid tissue, 3/6 splenic marginal zone lymphoma (SMZL), 1/4 chronic lymphocytic leukemia, 2/3 nodal marginal zone lymphoma (NMZL), 1/2 mantle cell lymphoma, 1 Burkitt lymphoma, and 1 B cell NHL that could not be classified), primary AL (2/2), and IgM-PN (1/1). The mutation was absent in five patients with Cryoglobulinemia, two with primary cold agglutinin disease and one with MM. The CXCR4 WHIM-like mutation was present in 10/42 patients with WM, 3/41 with NHL (1 DLBCL, 1 SMZL, and 1 NMZL), and 1/18 patients with IgM MGUS. Among the patients with NHL, those with the mutated MYD88 L265P genotype were younger and had lower level of IgG and IgA than the patients with the wild-type genotype. Patients with the mutated MYD88 L265P genotype with WM and MZL were compared. More male patients, higher levels of IgM and lower levels of LDH were found in the WM group. There was no significant difference in overall survival between the two groups. We present a study of the prevalence of the MYD88 L265P mutation and CXCR4 WHIM-like mutation in IgM RD. The MYD88 L265P mutation may play a key role in the pathogenesis of IgM monoclonal gammopathies. It would be interesting in the future to use MYD88 mutation status to differentiate among diseases.
Literatur
1.
Zurück zum Zitat Cao XX, Meng Q, Mao YY et al (2016) The clinical spectrum of IgM monoclonal gammopathy: a single center retrospective study of 377 patients. Leuk Res 46:85–88CrossRefPubMed Cao XX, Meng Q, Mao YY et al (2016) The clinical spectrum of IgM monoclonal gammopathy: a single center retrospective study of 377 patients. Leuk Res 46:85–88CrossRefPubMed
2.
Zurück zum Zitat Treon SP, Xu L, Yang G et al (2012) MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 367:826–833CrossRefPubMed Treon SP, Xu L, Yang G et al (2012) MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 367:826–833CrossRefPubMed
3.
Zurück zum Zitat Xu L, Hunter ZR, Yang G et al (2013) MYD88 L265P in Waldenstro ̈m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 121:2051–2058CrossRefPubMedPubMedCentral Xu L, Hunter ZR, Yang G et al (2013) MYD88 L265P in Waldenstro ̈m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 121:2051–2058CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Treon SP, Cao Y, Xu L et al (2014) Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia. Blood 123:2791–2796CrossRefPubMed Treon SP, Cao Y, Xu L et al (2014) Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia. Blood 123:2791–2796CrossRefPubMed
5.
Zurück zum Zitat Owen RG, Treon SP, Al-Katib A et al (2003) Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom’s macroglobulinemia. Semin Oncol 30:110–115CrossRefPubMed Owen RG, Treon SP, Al-Katib A et al (2003) Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom’s macroglobulinemia. Semin Oncol 30:110–115CrossRefPubMed
6.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of Tumours of Haematopoitetic and lymphoid tissues. IARC PRESS, Lyon Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of Tumours of Haematopoitetic and lymphoid tissues. IARC PRESS, Lyon
7.
Zurück zum Zitat Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33:2863–2869CrossRefPubMedPubMedCentral Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33:2863–2869CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Berentsen S, Tjønnfjord GE (2012) Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev 26:107–115CrossRefPubMed Berentsen S, Tjønnfjord GE (2012) Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev 26:107–115CrossRefPubMed
9.
Zurück zum Zitat Manuel RC, John HS, Maria CC, Bosch X (2012) The cryoglobulinaemias. Lancet 379:348–360CrossRef Manuel RC, John HS, Maria CC, Bosch X (2012) The cryoglobulinaemias. Lancet 379:348–360CrossRef
10.
Zurück zum Zitat Roccaro AM, Sacco A, Jimenez C et al (2014) C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood 123:4120–4131CrossRefPubMed Roccaro AM, Sacco A, Jimenez C et al (2014) C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood 123:4120–4131CrossRefPubMed
11.
Zurück zum Zitat Varettoni M, Zibellini S, Arcaini L et al (2013a) MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood 122:2284–2285CrossRefPubMed Varettoni M, Zibellini S, Arcaini L et al (2013a) MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood 122:2284–2285CrossRefPubMed
12.
Zurück zum Zitat Staiger AM, Ott MM, Parmentier S et al (2015) Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples. Br J Haematol 171:145–148CrossRefPubMed Staiger AM, Ott MM, Parmentier S et al (2015) Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples. Br J Haematol 171:145–148CrossRefPubMed
13.
Zurück zum Zitat Liu F, Karube K, Kato H et al (2012) Mutation analysis of NF-kappa B signal pathway-related genes in ocular MALT lymphoma. Int J Clin Exp Pathol 5:436–441PubMedPubMedCentral Liu F, Karube K, Kato H et al (2012) Mutation analysis of NF-kappa B signal pathway-related genes in ocular MALT lymphoma. Int J Clin Exp Pathol 5:436–441PubMedPubMedCentral
14.
Zurück zum Zitat Yan Q, Huang Y, Watkins AJ et al (2012) BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica 97:595–598CrossRefPubMedPubMedCentral Yan Q, Huang Y, Watkins AJ et al (2012) BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica 97:595–598CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Puente XS, Pinyol M, Quesada V et al (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101–105CrossRefPubMedPubMedCentral Puente XS, Pinyol M, Quesada V et al (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101–105CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Chakraborty R, Novak AJ, Ansell SM et al (2016) First report of MYD88L265P somatic mutation in IgM-associated light chain amyloidosis. Blood 127:2936–2938CrossRefPubMed Chakraborty R, Novak AJ, Ansell SM et al (2016) First report of MYD88L265P somatic mutation in IgM-associated light chain amyloidosis. Blood 127:2936–2938CrossRefPubMed
17.
Zurück zum Zitat Randen U, Troen G, Tierens A et al (2014) Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica 99:497–504CrossRefPubMedPubMedCentral Randen U, Troen G, Tierens A et al (2014) Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica 99:497–504CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Varettoni M, Arcaini L, Zibellini S et al (2013b) Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood 121:2522–2528CrossRefPubMed Varettoni M, Arcaini L, Zibellini S et al (2013b) Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood 121:2522–2528CrossRefPubMed
19.
Zurück zum Zitat Martinez-Lopez A, Curiel-Olmo S, Mollejo M et al (2015) MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma. Am J Surg Pathol 39:644–651CrossRefPubMed Martinez-Lopez A, Curiel-Olmo S, Mollejo M et al (2015) MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma. Am J Surg Pathol 39:644–651CrossRefPubMed
20.
Zurück zum Zitat Manasanch EE, Braylan R, Stetler-Stevenson M et al (2014) Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. Leuk Lymphoma 55:1402–1403CrossRefPubMed Manasanch EE, Braylan R, Stetler-Stevenson M et al (2014) Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. Leuk Lymphoma 55:1402–1403CrossRefPubMed
21.
Zurück zum Zitat Lin P, Hao S, Handy BC et al (2005) Lymphoid neoplasm associated with IgM paraprotein. A study of 382 patients. Am J Clin Pathol 123:200–205CrossRefPubMed Lin P, Hao S, Handy BC et al (2005) Lymphoid neoplasm associated with IgM paraprotein. A study of 382 patients. Am J Clin Pathol 123:200–205CrossRefPubMed
22.
Zurück zum Zitat Hunter ZR, Xu L, Yang G et al (2014) The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 123:1637–1646CrossRefPubMed Hunter ZR, Xu L, Yang G et al (2014) The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 123:1637–1646CrossRefPubMed
Metadaten
Titel
Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease
verfasst von
Xin-xin Cao
Qi Meng
Hao Cai
Tian-Hua He
Cong-li Zhang
Wei Su
Jian Sun
Yue Li
Wei Xu
Dao-bin Zhou
Jian Li
Publikationsdatum
09.03.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 6/2017
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-2968-z

Weitere Artikel der Ausgabe 6/2017

Annals of Hematology 6/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.